v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04459286 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : Nov. 3, 2021, 1:30 p.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : Nov. 3, 2021, 1:30 p.m. Source : ClinicalTrials.gov |
aeolagunju@oauife.edu.ng |
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-07-07 |
Recruitment status
Last imported at : March 3, 2022, 8:30 p.m. Source : ClinicalTrials.gov |
Terminated |
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Blind label |
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
multi-center |
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
inclusion criteria: - willingness and ability to provide written informed consent - at least 18 and not more than 75 years of age at study entry - sars-cov-2 infection confirmed by pcr test within 4 days before randomization - currently symptomatic (fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia) and at covid-19 isolation and treatment centre |
Exclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
- inability to take orally administered medication or food - known hypersensitivity to study medication - pregnant or lactating (unless practicing exclusive replacement feeding for the entire study duration) - participation in any other interventional trial for covid-19 (observational study co-enrollment allowed) - concurrent treatment with other agents with actual or possible direct-acting antiviral activity against sars-cov-2 less than 24 hours prior to study drug dosing - concurrent use of agents with known or uncertain interaction with study drugs, including ritonavir - requiring mechanical ventilation at screening - alanine aminotransferase (alt) or aspartate aminotransferase (ast) above 5 times upper limit of normal (uln) - creatinine clearance below 50 ml/min using the cockcroft-gault formula for participants above 18 years of age |
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Obafemi Awolowo University |
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
75 |
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Nigeria |
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Mild disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
1: Mild disease at enrollment |
Total sample size
Last imported at : Nov. 3, 2021, 1:30 p.m. Source : ClinicalTrials.gov |
57 |
primary outcome
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Difference in SARS-CoV-2 AUC;Time to SARS-CoV-2 negativity;Time to clinical improvement |
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m. Source : ClinicalTrials.gov |
Phase 2 |
Arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 1647, "treatment_name": "Atazanavir+nitazoxanide+ritonavir", "treatment_type": "Antivirals+antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |